US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.

feet at edge of pool
FDA is on the edge of some significant approvals in June. • Source: Shutterstock

The US FDA will be kept busy during the month of June, thanks to a hefty collection of nearly 25 Prescription Drug User Fee Act goal dates, but the drama is likely to ratchet up mid-month when high-profile decisions are due on a diverse range of products, including Roche Holding AG/Sarepta Therapeutics, Inc.’s SRP-9001 gene therapy for Duchenne muscular dystrophy (22 June target), Fabre-Kramer Pharmaceuticals’s long-gestating antidepressant Exxua (gepirone) (23 June goal date), F2G Ltd’s novel antifungal olorofim (17 June) and GlaxoSmithKline’s JAK1/JAK2/ACVR1 inhibitor momelotinib for myelofibrosis with anemia (16 June).

The month could close out with fireworks, the Pink Sheet’s US FDA Performance Tracker shows. BioMarin Pharmaceutical Inc.’s hemophilia...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By 

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By 

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.